Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: A double-blind, randomized trial

Journal of Internal Medicine

Volumn 239, Issue 3, 1996, Pages 253-260

  Lee, S H ^a   Chen, S A ^a   Chiang, C E ^a   Tai, C T ^a   Wen, Z C ^a   Wang, S P ^a   Chang, M S ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Atrial fibrillation; Propafenone; Quinidine

Indexed keywords

PROPAFENONE; QUINIDINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0030029968     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1996.451805000.x     Document Type: Article

References (23)

1. Podrid PJ. Oral antiarrhythmic drugs used for atrial fibrillation: clinical pharmacology. In: Falk RH, Podrid PJ, eds. Atrial Fibrillation: Mechanisms and Management. New York: Raven Press Ltd, 1992: 197-231.
2. Coplen SE, Antmann EM, Berbn JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990; 82: 1106-16.
3. Boissel JP, Wolf E, Gillet J. Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation. Eur Heart J 1981; 2: 49-55.
4. Schmid PC, Nelson LD, Mark AL, Heistad DD, Abboud FM. Inhibition of adrenergic vasoconstriction by quinidine. J Pharmacol Exp Ther 1974; 188: 124-34.
5. Mason JW, Winkle RA, Rider AK, Stenson EB, Harrison DC. The electrophysiologic effects of quinidine in the transplanted human heart. J Clin Invest 1977; 59: 481-9.
6. Dukes ID, Vaughan Williams EM. The multiple modes of action of propafenone. Eur Heart J 1984; 5: 115-25.
7. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol 1988; 4: 1005-11.
8. Kerr CR, Klein GJ, Axelson JE, Cooper JC. Propafenone for prevention of recurrent atrial fibrillation. Am J Cardiol 1988; 61: 914-16.
9. Porterfield JG, Porterfield LM. Therapeutic efficacy and safety of oral propafenone for atrial fibrillation. Am J Cardiol 1989; 63: 114-16.
10. Connolly SJ, Hoffert DL. Usefulness of propafenone for recurrent paroxysmal atrial fibrillation. Am J Cardiol 1989; 63: 817-19.
11. Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL. Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990; 15: 698-707.
12. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71: 558-63.
13. Hammill SC, Wood DL, Gersh BJ, Osborn MJ, Holmes DR. Propafenone for paroxysmal atrial fibrillation. Am J Cardiol 1988; 61: 473-4.
14. Seltzer A, Wray HW. Quinidine syncope paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 1964; 30: 17-26.
15. El-Sherif N, Bekheit SS, Henkin R. Quinidine-induced long QTU interval and torsades de points: role of bradycardia-dependent early afterdepolarizations. J Am Coll Cardiol 1989; 14: 252-7.
16. Dinh H, Murphy ML, Baker BJ, DeSoyza N. Propafenone: a new antiarrhythmic for treatment of chronic ventricular arrhythmias. Clin Prog Electrophysiol Pacing 1986; 4: 535-45.
17. Connolly SJ, Kates RE, Lebsack CS, Harrison DC, Winkle RA. Clinical pharmacology of propafenone. Circulation 1983; 68: 589-596.
18. Podrid PJ, Lown B. Propafenone: a new agent for ventricular arrhythmia. J Am Coll Cardiol 1984; 4: 117-25.
19. Hodges M, Salerno D, Grandrud G. Double-blind placebo-controlled evaluation of propafenone in suppressing ventricular ectopic activity. Am J Cardiol 1984; 54: 45D-50D.
20. Hammill SC. Use of propafenone in patients with supraventricular tachycardia. J Electrophysiol 1987; 1: 561-7.
21. McLeod AA, Stiles GL, Shand DG. Demonstration of beta adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. J Pharmacol Exp Ther 1984; 228: 461-6.
22. Ledda F, Mantelli L, Manzini S, Amerini S, Mugelli A. Electrophysiological and antiarrhythmic properties of propafenone in isolated cardiac preparations. J Cardiovasc Pharmacol 1981; 3: 1162-73.
23. Antman EM, Ludmer PL, McGowan N, Bosak M, Frideman PL. Transtelephonic electrocardiographic transmission for management of cardiac arrhythmias. Am J Cardiol 1986; 58: 1021-4.